ViewRay earns premarket clearance for MRI-guide radiotherapy system
ViewRay has received FDA 510(k) premarket notification clearance for its MRI-guided radiation therapy system.
The system provides continuous soft-tissue imaging during treatment so clinicians can see and record where radiation therapy is being delivered as it’s being delivered, according to Cleveland-based ViewRay.
The company recently closed a round of venture capital financing intended to advance the ViewRay system toward commercialization. The first ViewRay system is installed at the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis.
The system provides continuous soft-tissue imaging during treatment so clinicians can see and record where radiation therapy is being delivered as it’s being delivered, according to Cleveland-based ViewRay.
The company recently closed a round of venture capital financing intended to advance the ViewRay system toward commercialization. The first ViewRay system is installed at the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis.